In vivo administration of a monoclonal antibody against the type I IL-1 receptor inhibits the ability of mice to eliminate Mycobacterium paratuberculosis

1994 ◽  
Vol 55 (6) ◽  
pp. 719-722 ◽  
Author(s):  
K.B. Kenefick ◽  
J.L. Adams ◽  
H. Steinberg ◽  
C.J. Czuprynski
Keyword(s):  
Monoclonal Antibody ◽  
Type I ◽  
Mycobacterium Paratuberculosis ◽  
In Vivo Administration

scholarly journals Effect of in vivo administration of anti-CTLA-4 monoclonal antibody and IL-12 on the induction of low-dose oral tolerance

2002 ◽  
Vol 130 (2) ◽  
pp. 196-203 ◽  
Author(s):  
K. S. BARONE ◽  
B. HERMS ◽  
L. KARLOSKY ◽  
S. MURRAY ◽  
J. QUALLS
Keyword(s):  
Monoclonal Antibody ◽  
Oral Tolerance ◽  
Low Dose ◽  
Dose Oral ◽  
In Vivo Administration

IN VIVO ADMINISTRATION OF ANTI-MURINE CD3 MONOCLONAL ANTIBODY INDUCES SELECTIVE, LONG-TERM ANERGY IN CD8+ T CELLS

1996 ◽  
Vol 61 (5) ◽  
pp. 798-803 ◽  
Author(s):  
E. Steve Woodle ◽  
Shafi Hussein ◽  
Jeffrey A. Bluestone
Keyword(s):  
Monoclonal Antibody ◽  
T Cells ◽  
Cd8 T Cells ◽  
In Vivo Administration

scholarly journals A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo

Hepatology ◽  
2011 ◽  
Vol 55 (2) ◽  
pp. 364-372 ◽  
Author(s):  
Philip Meuleman ◽  
Maria Teresa Catanese ◽  
Lieven Verhoye ◽  
Isabelle Desombere ◽  
Ali Farhoudi ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Human Monoclonal Antibody ◽  
Scavenger Receptor ◽  
Type I ◽  
Hepatitis C Virus Infection ◽  
Viral Spread ◽  
Scavenger Receptor Class ◽  
Class B

scholarly journals Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10) [see comments]

Blood ◽  
1990 ◽  
Vol 75 (4) ◽  
pp. 1017-1023 ◽  
Author(s):  
P Herve ◽  
J Wijdenes ◽  
JP Bergerat ◽  
P Bordigoni ◽  
N Milpied ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Graft Versus Host Disease ◽  
Interleukin 2 ◽  
Complete Response ◽  
Host Disease ◽  
Graft Versus Host ◽  
In Vivo Administration ◽  
Acute Graft ◽  
Receptor Monoclonal Antibody

Abstract In a multicenter pilot study, 32 patients showing steroid-resistant acute graft-versus-host disease (GVHD) were treated by in vivo administration of anti-interleukin-2 (IL-2) receptor monoclonal antibody (MoAb B-B10). Twenty-three patients received marrow from HLA- matched related donors, four from matched unrelated donors and five from partially matched related donors. The overall grade of GVHD was II in 16 patients, III in two, and IV in five. Five milligrams of B-B10 MoAb was infused in bolus daily for 10 days and then every second day for a further 10 days in an attempt to reduce GVHD recurrence. No clinical side effects were noted during the B-B10 treatment period. A complete response (CR) acute GVHD was achieved in 21 patients (65.6%). Six patients (18.7%) showed partial improvement (PR) and 5 patients (15.6%) no response (NR). A significant factor associated with GVHD response was the delay between the onset of the GVHD and the first day of B-B10 infusion. The earlier B-B10 was introduced, the greater the probability of CR (P = .03). There was no correlation between the serum B-B10 level and GVHD response (P = .69). There was, however, a significant correlation between the clinical response and the B-B10 kinetics as a function of time: serum B-B10 levels attained a plateau level more rapidly in the CR group than in the PR/NR group. Among the 26 complete and partial evaluable responders, GVHD recurred in 10 cases (38.4%). Host anti-B-B10 MoAb immune response occurred in only one (7.1%) of the 14 patients analyzed. Fourteen of the 32 patients (43.7%) are currently alive between 2 and 14 months after GVHD treatment with B- B10 was completed.

scholarly journals In Vivo Administration of a PKA Type I Inhibitor (Rp-8-Br-cAMPS) Restores T-Cell Responses in Retrovirus-Infected Mice

2008 ◽  
Vol 1 (1) ◽  
pp. 20-24 ◽  
Author(s):  
Btissam Nayjib ◽  
Mustapha Zeddou ◽  
Pierre Drion ◽  
Jacques Boniver ◽  
Kjetil Tasken ◽  
...  
Keyword(s):  
T Cell ◽  
T Cell Responses ◽  
Type I ◽  
Cell Responses ◽  
In Vivo Administration

Selective Depletion of Rat Neutrophils by In Vivo Administration of a Monoclonal Antibody

1989 ◽  
Vol 46 (2) ◽  
pp. 96-102 ◽  
Author(s):  
Sakae Sekiya ◽  
Seiji Gotoh ◽  
Takao Yamashita ◽  
Tadashi Watanabe ◽  
Susumu Saitoh ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Selective Depletion ◽  
In Vivo Administration

The Antitumor Activity Induced by the in Vivo Administration of Activated B Cells Bound to Anti-CD3 Monoclonal Antibody

1995 ◽  
Vol 161 (1) ◽  
pp. 132-137 ◽  
Author(s):  
Mamoru Harada ◽  
Tadao Okamoto ◽  
Shin Kurosawa ◽  
Yoshihiro Shinomiya ◽  
Osamu Ito ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cells ◽  
Antitumor Activity ◽  
In Vivo Administration ◽  
Activated B Cells

In Vivo Administration of Antibodies Against Type I Collagen in Rat: The Specific Accumulation in Spleen

1987 ◽  
Vol 7 (6) ◽  
pp. 383-397 ◽  
Author(s):  
Gregory L. Idelson ◽  
Vladimir R. Muzykantov ◽  
Elena E. Chekneva ◽  
Alexander A. Shnyra ◽  
Boris V. Shekhonin ◽  
...  
Keyword(s):  
Type I Collagen ◽  
Type I ◽  
Specific Accumulation ◽  
In Vivo Administration
Sign in / Sign up

Export Citation Format

Share Document